Drugs / MANITIMUS
MANITIMUS
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00104338 | Jan 2005 → Aug 2006 | kidney disorder, polyomavirus infectious disease | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00282230 | Nov 2003 → Oct 2005 | — | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00189735 | Sep 2003 → Oct 2005 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00451932 | Oct 2002 → Sep 2005 | — | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MANITIMUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107757 ↗ |
| Known as | FK778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00189735 ↗ |
| Known as | HMR 1715 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107757 ↗ |
| Known as | MNA-715 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107757 ↗ |
| Modality | Small molecule | “the leflunomide derivative FK778” PMID 39382091 ↗ Oct 2024 |
| Route | Oral | “a new oral immunosuppressant agent compared to standard care” NCT00104338 ↗ |